Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Drug-resistant tuberculosis.

P A Willcox1

  • 1Respiratory Clinic, Groote Schuur Hospital and University of Cape Town, South Africa.

Current Opinion in Pulmonary Medicine
|April 27, 2000
PubMed
Summary
This summary is machine-generated.

Drug-resistant tuberculosis is a growing global concern with limited new treatments. Understanding its genetic basis and improving patient adherence are key to combating this man-made public health challenge.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatment outcome and follow-up of multidrug-resistant tuberculosis patients, West Coast/Winelands, South Africa, 1992-2002.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2008
Same author

A prospective, randomized, multicenter comparative study of clinafloxacin versus a ceftriaxone-based regimen in the treatment of hospitalized patients with community-acquired pneumonia.

Scandinavian journal of infectious diseases·2002
Same author

Drug-resistant tuberculosis: worldwide trends, problems specific to Eastern Europe and other hotspots, and the threat to developing countries.

Current opinion in pulmonary medicine·2001
Same author

Tuberculous tenosynovitis and carpal tunnel syndrome as a presentation of HIV disease.

The Journal of infection·2000
Same author

A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia.

Scandinavian journal of infectious diseases·1998
Same author

Community-acquired Staphylococcus aureus bacteraemia in patients who do not abuse intravenous drugs.

QJM : monthly journal of the Association of Physicians·1998
Same journal

Toward precision imaging in interstitial lung disease: advances in quantitative imaging and artificial intelligence.

Current opinion in pulmonary medicine·2026
Same journal

Oxygen therapy in interstitial lung disease - navigating benefit and burden.

Current opinion in pulmonary medicine·2026
Same journal

Preclinical and clinical advances in pulmonary hypertension associated with systemic sclerosis.

Current opinion in pulmonary medicine·2026
Same journal

Advancing lung transplantation: current challenges and future directions.

Current opinion in pulmonary medicine·2026
Same journal

Association between upper airway obstruction and pulmonary hypertension in children with Down syndrome.

Current opinion in pulmonary medicine·2026
Same journal

Molecular mechanisms of environmental risk factors for interstitial lung disease.

Current opinion in pulmonary medicine·2026
See all related articles

Area of Science:

  • Microbiology
  • Public Health
  • Genetics

Background:

  • Growing global concern over drug-resistant tuberculosis (TB).
  • Absence of new TB drug classes since the 1960s exacerbates treatment challenges.
  • The precise global extent of drug resistance in TB is not well-defined.

Purpose of the Study:

  • To investigate the global extent of drug-resistant tuberculosis.
  • To explore advances in understanding the genetic basis of drug resistance in Mycobacterium tuberculosis.
  • To identify potential new drug targets for TB treatment.

Main Methods:

  • Collaborative initiatives by the World Health Organization and the International Union Against Tuberculosis and Lung Disease.
  • Whole genome sequencing of Mycobacterium tuberculosis.

Related Experiment Videos

  • Analysis of factors contributing to treatment nonadherence.

    • Main Results:

    • Advances in understanding the genetic underpinnings of drug resistance in TB.
    • Emergence of potential new drug targets following Mycobacterium tuberculosis genome sequencing.
    • Modest average cure rates persist, with nonadherence remaining a significant obstacle.

    Conclusions:

    • Drug resistance in TB is a preventable, man-made issue.
    • Directly Observed Therapy, Short-course (DOTS) is crucial for preventing drug resistance.
    • Continued research into genetic factors and adherence strategies is essential for improving TB treatment outcomes.